Crossmark

Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1007/s00432-023-05431-5

Published Online: 2023-09-28

Published Print: 2023-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bratova, Monika

Skrickova, Jana

Matusikova, Magda

Hrabcova, Karolina

Havel, Libor

Koubkova, Leona

Hrnciarik, Michal

Krejci, Jana

Fischer, Ondrej

Svaton, Martin

Brat, Kristian https://orcid.org/0000-0003-1674-228X
License Information

Text and Data Mining valid from 2023-09-28

Version of Record valid from 2023-09-28
More Information

Article History

Received: 11 July 2023

Accepted: 13 September 2023

First Online: 28 September 2023

Declarations

:

: Author MB received speaker and consultant honoraria from Astra Zeneca CZ, Roche CZ, MSD CZ, and Bristol-Myers Squibb CZ. The other authors declare no conflicts of interest relevant to this study.

Document is current

Any future updates will be listed below